马应龙八宝Mabo's品牌怎么样 申请店铺

我要投票 马应龙八宝Mabo's在眼霜行业中的票数:773 更新时间:2025-12-14
马应龙八宝Mabo's是哪个国家的品牌?「马应龙八宝Mabo's」是 马应龙药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北武汉,由创始人陈平经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力马应龙八宝Mabo's品牌出海!将品牌入驻外推网,定制马应龙八宝Mabo's品牌推广信息,可以显著提高马应龙八宝Mabo's产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

马应龙八宝Mabo's怎么样

马应龙是一家经国家商务部认定的中华老字号企业,创始于公元1582年。经过多年持续快速健康发展,马应龙已经成为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的医药类上市公司。

公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年,马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心,马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证,获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证,在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2009年“中国最具价值品牌500强”排行榜中,马应龙名列第213位,品牌价值达到了40.01亿元。2006年马应龙荣获国家工商总局认定的“驰名保护”。2009年,马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”

公司股票于2004年在上海证券交易所上市,由此获得了持续融资的通道和规范营运的平台。2007年,公司股票被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股,标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化,公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康,为股东创造财富,为员工创造机会,为社会创造效益”的经营宗旨,倡导“以真修心,以勤修为”的哲学观,倡导“稳健经营、协调发展”的经营观,倡导“资源增值”的价值观,弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任,在品牌经营战略的指引下与时俱进,继往开来。


Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Commerce. It was founded in 1582 ad. After years of sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals and other fields. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. In the 2009 "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, Ma Yinglong ranked 213, with the brand value reaching 4.001 billion yuan. In 2006, Ma Yinglong was awarded "famous protection" by the State Administration for Industry and commerce. In 2009, Ma Yinglong was listed on Shanghai Stock Exchange in 2004 as one of the "top 15 Chinese over-the-counter drug brand enterprises" by China over-the-counter drug association, thus obtaining a channel for continuous financing and a platform for standardized operation. In 2007, the company's stock was selected as the sample stock of China's listed corporate governance index by Shanghai Stock Exchange and China Securities Index company, marking that the level of corporate governance was highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接: https://brand.waitui.com/92904fecd.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

应对老年护理刚需,四部门发布《老年护理服务能力提升行动方案》

近日,国家卫生健康委、国家医保局、国家中医药局和国家疾控局四部门发布《老年护理服务能力提升行动方案》(以下简称《行动方案》)提出,到2027年,老年护理资源有效扩容,覆盖机构、社区、居家的老年护理服务体系逐步完善,从业人员服务能力不断提升,老年护理服务持续改善,服务连续性、可及性、规范性持续提高,老年人获得感不断增强。提升老年护理服务能力是深入贯彻实施积极应对人口老龄化国家战略的具体举措。截至2024年底,我国60岁及以上人口数达3.1亿,占总人口的22%,老年人特别是失能老年人对医疗护理服务呈现迫切的刚性需求。(央视新闻)

2小时前

消息人士称英伟达考虑提高H200芯片产量

消息人士称,英伟达考虑提高H200芯片产量。(新浪财经)

2小时前

中国造高端工业母机在沈阳下线交付

记者13日从通用技术沈阳机床获悉,由通用技术集团与东方电气集团联合研发的4台高端五轴联动数控机床12日在沈阳下线交付。这一合作在取得重大技术突破的同时,还打破了“研用脱节”的产业困境,开创了国产工业母机研制的新模式。长期以来,国产高端数控机床面临“研发投入大、周期长、验证难”的系统性瓶颈——企业闭门研发与市场实际需求脱节,产品因缺乏真实工况下的长期验证,陷入“用户不愿用、不敢用,技术难迭代、难成熟”的恶性循环,严重制约产业高质量发展。(中新网)

2小时前

金融时报:将坚持内需主导放在首位

金融时报评论员发布文章称,12月10日至11日,中央经济工作会议在京举行。会议聚焦“当前怎么看”和“明年怎么干”,为中国经济高质量发展把舵定向。站在“十四五”规划收官与“十五五”规划谋篇的历史交汇点,会议强调持续扩大内需、优化供给,将“坚持内需主导,建设强大国内市场”确定为明年经济工作重点任务之首。未来一个时期,我国国内市场主导国民经济循环的特征将更为明显。在内外部发展环境更趋严峻复杂的大背景下,只有坚持立足国内,全方位扩大内需、建设强大国内市场,增强发展主动性,才能够在国际风云变幻中,牢牢把握发展主动权。着眼明年经济社会发展目标任务,做强国内大循环,建设强大国内市场,以国内循环的稳定性对冲国际循环的不确定性,必须坚持内需的主导地位。坚持内需主导,全方位扩大国内需求,要大力提振居民消费。坚持内需主导,全方位扩大国内需求,要推动投资止跌回稳。将坚持内需主导放在首位,是党和国家对当前经济形势的深刻洞察。要全面贯彻明年经济工作的总体要求和政策取向,加快培育完整内需体系,形成消费和投资相互促进的良性循环,将超大规模市场的潜力转化为现实增长动力。

2小时前

脑虎科技:公司“三全”脑机接口产品成功完成首例临床试验

在今日举行的2025天桥脑科学研究院脑机接口与人工智能论坛中,脑虎科技方面表示,公司自主研发的国内首款、国际第二款内置电池的全植入、全无线、全功能(“三全”)脑机接口产品,在复旦大学附属华山医院毛颖、陈亮教授团队的主持下,成功完成首例临床试验。(财联社)

2小时前

本页详细列出关于马应龙八宝Mabo's的品牌信息,含品牌所属公司介绍,马应龙八宝Mabo's所处行业的品牌地位及优势。
咨询